Article
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Mayo Clinic proceedings - 1 Apr 2008
Pardanani Animesh, Lasho Terra L, Hussein Kebede, Schwager Susan M, Finke Cristy M, Pruthi Rajiv K, Tefferi Ayalew
Abstract excerpt
The JAK2V617F mutation is recurrent in polycythemia vera and essential thrombocythemia, which are myeloproliferative neoplasms (MPNs) frequently associated with arterial and/or venous thromboembolism. More recently, the JAK2V617F mutation has been identified as a surrogate marker for subclinical or "occult" clonal myeloproliferation in patients with splanchnic venous thrombosis. However, information is limited...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.